New drug aims to tame hepatitis b in HIV patients

NCT ID NCT05551273

Completed Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial tested an oral drug called selgantolimod in 29 adults with both chronic hepatitis B and HIV. Participants had been on stable antiviral therapy for both viruses for at least 5 years. The study aimed to see if the drug is safe and can lower hepatitis B surface antigen levels in the blood, which is a marker of the virus.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selgantolimod (an oral drug that stimulates the immune system)
What this could lead to: If successful, this could point toward a way to lower hepatitis B virus levels in people who also have HIV, potentially reducing liver damage over time.
What could go wrong: This is a small, early-phase trial focused on safety and immune response, not a cure. The drug may not significantly reduce hepatitis B markers, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B HIV INFECTIONS

Contacts and locations

Locations

Barranco CRS (Site 11301)

Lima, 04, Peru
Case CRS (Site ID# 2501)

Cleveland, Ohio, 44106, United States
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site 31784)

Chiang Mai, 50200, Thailand
Cincinnati Clinical Research Site (Site 2401)

Cincinnati, Ohio, 45267-0405, United States
Greensboro CRS (Site# 3203)

Greensboro, North Carolina, 27401, United States
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID# 12101)

Rio de Janeiro, 21040-360, Brazil
Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site 12201)

Porto Alegre, Rio Grande do Sul, 91350-180, Brazil
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site 31802)

Pathum Wan, Bangkok, 10330, Thailand
The Ponce de Leon Center CRS (Site 5802)

Atlanta, Georgia, 30308, United States
UCSD Antiviral Research Center CRS (Site 701)

San Diego, California, 92103, United States
Univ of Pittsburgh (Site 1001)

Pittsburgh, Pennsylvania, 15213, United States
Weill Cornell Chelsea CRS (Site 7804)

New York, New York, 10011, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.